Eric Adams
Chief Executive Officer at INMED PHARMACEUTICALS INC.
Net worth: 16 001 $ as of 2024-03-30
Profile
Eric A.
Adams is the President, Chief Executive Officer & Director of InMed Pharmaceuticals, Inc. He was the Chief Executive Officer of Ronin8 Technologies Ltd.
from 2014 to 2015.
He was the Director-Oncology Marketing at QLT, Inc. from 1998 to 2002.
He was a Non-Executive Director at enGene, Inc. from 2011 to 2013.
He was the Senior Manager-Business Development at Abbott Laboratories from 1992 to 1996.
He was the Country Manager at Fresenius SE & Co. KGaA from 1988 to 1992.
Mr. Adams has a graduate degree from the University of South Carolina and an undergraduate degree from the University of Southern Indiana.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-02-19 | 43,959 ( 0.73% ) | 16 001 $ | 2024-03-30 |
Eric Adams active positions
| Companies | Position | Start |
|---|---|---|
| INMED PHARMACEUTICALS INC. | Chief Executive Officer | 2016-06-15 |
Former positions of Eric Adams
| Companies | Position | End |
|---|---|---|
Ronin8 Technologies Ltd.
 Ronin8 Technologies Ltd. Environmental ServicesIndustrial Services Ronin8 Technologies Ltd. provides materials recovery facilities. It captures the metals in electronic waste without destroying the non-metals. The company was founded by Bruce Sifton and Peter Holgate in 2015 and is headquartered in Vancouver, Canada. | Chief Executive Officer | 2015-01-31 |
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Chief Executive Officer | 2013-06-30 |
QLT, Inc.
 QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Sales & Marketing | 2002-11-30 |
| ABBOTT LABORATORIES | Corporate Officer/Principal | 1996-07-31 |
| FRESENIUS SE & CO. KGAA | Corporate Officer/Principal | 1992-05-31 |
Training of Eric Adams
| University of South Carolina | Graduate Degree |
| University of Southern Indiana | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| FRESENIUS SE & CO. KGAA | Health Technology |
| INMED PHARMACEUTICALS INC. | Health Technology |
| Private companies | 3 |
|---|---|
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Commercial Services |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
Ronin8 Technologies Ltd.
Ronin8 Technologies Ltd. Environmental ServicesIndustrial Services Ronin8 Technologies Ltd. provides materials recovery facilities. It captures the metals in electronic waste without destroying the non-metals. The company was founded by Bruce Sifton and Peter Holgate in 2015 and is headquartered in Vancouver, Canada. | Industrial Services |
- Stock Market
- Insiders
- Eric Adams
